Joomla gallery extension by joomlashine.com
Main Promo Images
Latest news on Friedreich's Ataxia research
Updated results from clinical trials and research initiatives
Friedreich's Ataxia fundraising activities and staying in touch
Participate and stay informed about our fundraising events. Take part in our Facebook community with FA patients, relatives, researchers and friends from all around the world!
18 Jun 2008 | 07:09 PM ET
EUGENE, Ore., Jun 18, 2008 (BUSINESS WIRE). MitoSciences has today released two new products for measuring Mitochondrial Biogenesis, a crucial biological process that is receiving increased attention due to its link to increased life span and greater resistance to disease.
Mitochondrial Biogenesis is at the center of highly-publicized recent studies describing the positive effects of resveratrol (the healthful component in red wine and an activator of proteins called sirtuins) and the creation of the so-called Super Mouse.
The other side of Mitochondrial Biogenesis involves negative effects, and pharmaceutical companies have recognized for years that antibiotic and antiviral drugs can significantly inhibit Mitochondrial Biogenesis. Developers of drugs for HIV patients are particularly aware of such effects, but methods for rapidly evaluating the toxic effects of HIV drugs on patients have been limited.
MitoSciences is offering two new solutions to researchers with the release of the MitoProfile(R) Biogenesis kits. The MS631 MitoProfile(R) Biogenesis Dipstick Kit is designed for point-of-care testing, and the MS641 MitoProfile(R) Biogenesis Microplate Kit is designed for high-throughput analysis.
"Our hope is that these new kits will provide useful tools to support some very promising areas of disease prevention research," said Jean-Paul Audette, president of MitoSciences, "while also supporting ongoing research into the best and safest ways to administer antiviral and antibiotic drugs."
Both tests are highly sensitive, while also being faster, easier, and less expensive than existing methods for evaluating Mitochondrial Biogenesis. Both kits are for research use only, not for diagnostic testing, although the Biogenesis Dipstick Kit has been approved by the FDA For Investigational Use Only, a designation for tests that are undergoing clinical validation.
Also released today were several new products for studying apoptosis and Friedreich's Ataxia (the most common form of inherited ataxia):
- MSF41 Microplate Assay Kit for Frataxin is a quantitative assay for measuring frataxin, a protein that is decreased in Friedreich's Ataxia (FA) patients. This kit is a high-throughput complement to the existing Dipstick Kit for Frataxin (MSF31), and is particularly suited to drug developers working on FA therapies.
- MSF42 Recombinant Human Frataxin provides very useful control material to users of both MSF31 and MSF41 for use in generating standard curves.
- MSA42 Microplate Assay Kit for Apoptosis-Inducing Factor (AIF) is a high-throughput complement to the existing MSA31 Dipstick Assay Kit for AIF, providing another tool for analyzing AIF's role in apoptosis, oxidative stress, and Complex I assembly.
About MitoSciences Inc.
MitoSciences is a developer and manufacturer of monoclonal antibodies and immunoassays for use in understanding mitochondrial function and metabolism. MitoSciences' products are used by pharmaceutical companies, clinical laboratories, and basic researchers to unlock the role of metabolic enzymes in disease, drug therapy, and drug toxicology. With an emphasis on developing assays that can measure multiple parameters in a single sample, MitoSciences is supporting the rapidly growing fields of systems biology and personalized medicine.
SOURCE: MitoSciences Inc.
Jean-Paul Audette, president, 541-284-1800
If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.
The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.
Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!
Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:
1) Gene Therapy for Friedreich's Ataxia research project:
The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.
2) Frataxin delivery research project:
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.
The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.